Congo begins trial of Gilead's ($GILD) experimental antiviral for Ebola Bundibugyo

Written By yadhziwikwknxz

Researchers in the Democratic Republic of Congo have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.

yadhziwikwknxz
Previous

GSK to Seek FDA Approval for Jemperli in Rectal Cancer After Phase 2 Success
Next

FDA approves Vertex's Casgevy for children as young as 2, opening door to thousands more patients